Mitochondrial dysfunction rather than mtDNA sequence mutation is responsible for the multi-drug resistance of small

Oncology Reports
|October 28, 2015
PubMed

Insights

Mitochondrial DNA mutations drive small cell lung cancer (SCLC) development. However, mitochondrial dysfunction, not mtDNA mutations, contributes to chemotherapy drug resistance in SCLC by impacting the reactive oxygen species-mediated apoptotic pathway.

Area of Science:

  • Oncology
  • Mitochondrial Biology
  • Genetics

Background:

  • Small cell lung cancer (SCLC) survival is limited by chemotherapy resistance.
  • Mitochondrial DNA (mtDNA) mutations are implicated in tumorigenesis and drug resistance.
  • Mitochondrial dysfunction is hypothesized to drive SCLC occurrence and progression.

Purpose of the Study:

  • To investigate the role of mtDNA mutations in SCLC tumorigenesis.
  • To determine the association between mtDNA and SCLC drug sensitivity.
  • To explore the contribution of mitochondrial dysfunction to multidrug resistance (MDR) in SCLC.

Main Methods:

  • Sequencing of mtDNA from drug-sensitive (H446) and drug-insensitive (H446/CDDP) SCLC cell lines.
  • Comparison of mtDNA sequences with the revised Cambridge reference sequence (rCRS).
  • Assessment of mitochondrial function, including lactic acid and reactive oxygen species (ROS) production, and analysis of the mitochondrial apoptotic pathway.

Main Results:

  • No significant differences in mtDNA sequences were found between H446 and H446/CDDP cells, though spot mutations were observed relative to rCRS.
  • H446 cells exhibited higher lactic acid and ROS synthesis than H446/CDDP cells upon cisplatin challenge.
  • Increased expression of Bax, cleaved caspase-3, and cleaved caspase-9 was noted in H446 cells compared to H446/CDDP cells post-cisplatin stimulation.

Conclusions:

  • mtDNA mutations are linked to SCLC tumorigenesis but not directly to drug sensitivity.
  • Mitochondrial dysfunction, potentially due to varied mitochondrium content, contributes to SCLC multidrug resistance.
  • The ROS-mediated mitochondrial apoptotic pathway is a key factor in SCLC drug resistance.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Mitochondrial Membranes01:45

Mitochondrial Membranes

A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
17.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68